SecBot SecBot
PRESS-RELEASE ·Filed Aug 11, 2026

BCAX

Bicara Therapeutics Inc.
MIXED
Impact 6/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The leadership transition at CEO and CFO levels introduces execution risk ahead of a pivotal data readout in mid-2027. Monitor for any enrollment delays or changes in trial guidance. The cash runway into H1 2029 provides a buffer, but the widening net loss and increased spending warrant close attention to future capital needs.

DirectionMixed
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.76
T+0 close · Aug 11, 2026 · via day close
Latest settled
−62.58%
T+60 · $8.89
Vs SPY
−62.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $23.76entry
  2. T+1 · 3mo ago +3.66%α +3.41% · $24.63
  3. T+5 · 3mo ago +4.88%α +5.29% · $24.92
  4. T+20 · 2mo ago −0.51%α +0.55% · $23.64
  5. T+60 · 13d ago −62.58%α −62.10% · $8.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bicara Therapeutics reported Q2 2026 results with a net loss of $0.82 per share, slightly better than the $0.83 consensus estimate. The filing is dominated by a major leadership transition, with CEO Claire Mazumdar stepping down effective January 2027 and President/COO Ryan Cohlhepp taking over, alongside several other C-suite changes. The company's pivotal FORTIFI-HN01 trial remains on track for an interim analysis in mid-2027, and cash runway extends into H1 2029, but the leadership overhaul introduces execution risk at a critical juncture.

Key Financial Metrics

EPS
−$0.82
est −$0.83 · +1.2%
Rating
in line

Key Facts

  • Net loss of $0.82 per share vs $0.83 consensus (0.7% beat)
  • CEO Claire Mazumdar to step down Jan 2027, succeeded by COO Ryan Cohlhepp
  • CFO Ivan Hyep replaced by Jenn Larson effective Aug 12, 2026
  • FORTIFI-HN01 pivotal trial substantially enrolled by year-end, interim analysis mid-2027
  • Cash, equivalents and marketable securities $497.3M, funding operations into H1 2029
  • R&D expenses $45.8M (up 85% YoY), G&A $14.2M (up 97% YoY)

Financial Impact

Net loss widened to $55.4M from $27.4M YoY; cash burn accelerating as trial enrollment ramps

net losscashR&D expensesG&A expenses

Risk Factors

  • Leadership transition may disrupt trial execution or strategic direction
  • Widening net loss and increased R&D spend could necessitate future capital raises
  • Pivotal trial interim analysis not expected until mid-2027, leaving a long period without catalysts

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
81% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3342597

Track record

26 reports on BCAX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
  2. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  3. Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  4. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
  5. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
  7. Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
  8. Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
  9. Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (10h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026